Pharma BD Deal Intelligence
A $5.7B all-stock deal that gave Danaher a foothold in antibodies and proteomic research tools through Abcam. The acquisition strengthened Danaher's life sciences reagents portfolio, expanding its reach into protein-level research tools beyond its existing diagnostics base.
Danaher agreed to acquire antibody and reagent firm Abcam for $5.7 billion, with Abcam to operate as a standalone operating company within Danaher's Life…
Danaher has finalized its takeover of Abcam, a UK-based life sciences firm specializing in antibodies and consumables, for $5.7 billion in cash despite…
Post-close analyst review: Abcam integration into Danaher's Life Sciences segment ongoing; DHR trading ~11% below consensus target and ~13.8% below estimated…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Danaher acquired Abcam for $5.7B for antibodies, reagents, and proteomic research tools.
$13.4B Global Market · $550M Abcam Expected 2024 Revenue
Life science research reagents include antibodies, proteins, assays, and biomarkers used in basic research, drug discovery, and diagnostic development. The market is driven by government research funding, pharmaceutical R&D investment, and expanding biotech activity globally.
The research reagents market was fragmented with Abcam, Thermo Fisher, and Bio-Techne as leading suppliers. Abcam's differentiation lay in its curated antibody catalog with extensive validation data. The acquisition strengthened Danaher's Life Sciences segment alongside Beckman Coulter and Leica Microsystems.
Danaher to acquire Abcam for $24/share, gaining antibodies, reagents, and proteomic tools.
Closed ahead of schedule. Abcam became wholly owned subsidiary; Nasdaq trading suspended.
Abcam integrated as independent unit within Danaher, benefiting from portfolio scale.
See timeline for full assessment. Assessment of Danaher Corporation's $5.7B acquisition of Abcam PLC and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Danaher Corporation / Abcam PLC (this deal) | 2023 | $5.7B | 77 |
| Danaher Corporation / Pall Corporation | 2015 | $13.6B | 77 |
| Danaher Corporation / GE Life Sciences Biopharma Business (now Cytiva) | 2019 | $21.4B | 76 |
| Summit Therapeutics plc / Akeso Inc. | 2023 | $4.5B | 79 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
| AstraZeneca PLC / CinCor Pharma Inc. | 2023 | $1.8B | 78 |
| Merck & Co. Inc. / Prometheus Biosciences Inc. | 2023 | $10.8B | 77 |
← Browse all deals · How we score deals
More: 2023 deals · Danaher Corporation deals